The FDA has issued an EUA for the investigational monoclonal antibody therapy bamlanivimab for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients.
ACEP's Clinical Summary of Bamlanivimab
ACEP Infographic - Should you consider using Bamlanivimab to treat your COVID patient?
FDA's Letter of Emergency Use Authorization (EUA)
CMS: Medicare Monoclonal Antibody COVID-19 Infusion Program Instruction
Casirivimab + Imdevimab Baseball Cards
From Eli Lilly and Company
Fact Sheet for Health Care Providers EUA of Bamlanivimab
Fact Sheet for Patients, Parents and Caregivers EUA of Bamlanivimab
Lilly Bamlanivimab Antibody Playbook
From Regeneron
Casirivimab and Imdevimab Letter and Resources.pdf
